Bone Marrow-on-Chip as smart sensor of lung cancer relapse
BuonMarrow aims to develop an innovative in vitro device using bone marrow mesenchymal stromal cells to early detect lung cancer relapse, enhancing personalized treatment and patient survival.
Projectdetails
Introduction
In the past 40 years, the overall survival rate for people affected by tumors has doubled, with about 50% of patients now surviving their disease for 10 years or more. Nonetheless, some cancers (e.g., lung cancer) still have a poor survival rate.
Problem Statement
A major cause of lung cancer mortality is represented by disease relapse, occurring when few of the original cancer cells survive the initial treatment, causing primary tumor recurrence. Currently, no options are available to predict the risk of lung cancer relapse, which is only diagnosed late based on radiological evidence.
Urgent Need
Hence, the ability to early detect lung cancer relapse represents an urgent and unmet need, since a fast and tailored treatment could dramatically increase patients’ survival rate.
Project Hypothesis
BuonMarrow lays on the groundbreaking hypothesis, supported by our Consortium preliminary clinical evidence, that bone marrow mesenchymal stromal cells (BM-MSC) may be educated upon cancer mediators exposure and acquire a long-term memory-like response, which is amplified when exposed to a secondary tumor.
Technological Approach
Owing to breakthrough technologies available in the Consortium, including:
- Organ-on-chip
- Innovative optical sensors
- Biological modeling of the bone marrow niche
BuonMarrow partners will develop an in vitro miniaturized bone marrow device able to harness the amplified BM-MSC response generated by liquid biopsy of lung cancer patients, thus acting as a biological sensor for the early detection of relapse.
Research Methodology
A combination of retrospective and prospective clinical studies will allow us to:
- Calibrate the sensor
- Validate the sensor
This will deliver an unprecedented tool to assist the decision-making process for lung cancer patients.
Expected Impact
We expect to significantly improve oncological treatments, building on a personalized medicine approach to increase patient survival and well-being, thereby deeply impacting the EU’s socio-economic environment.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.999.835 |
Totale projectbegroting | € 2.999.835 |
Tijdlijn
Startdatum | 1-3-2024 |
Einddatum | 28-2-2027 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- POLITECNICO DI MILANOpenvoerder
- FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA
- LUNDS UNIVERSITET
- FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation. | EIC Pathfinder | € 2.996.550 | 2022 | Details |
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images. | EIC Pathfinder | € 2.744.300 | 2022 | Details |
Dynamic Spatio-Temporal Modulation of Light by Phononic ArchitecturesDynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements. | EIC Pathfinder | € 2.552.277 | 2022 | Details |
Emerging technologies for crystal-based gamma-ray light sourcesTECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology. | EIC Pathfinder | € 2.643.187 | 2022 | Details |
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"
The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation.
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.
The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images.
Dynamic Spatio-Temporal Modulation of Light by Phononic Architectures
Dynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements.
Emerging technologies for crystal-based gamma-ray light sources
TECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Nano-assisted digitalizing of cancer phenotyping for immunotherapyThe ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes. | ERC COG | € 1.993.875 | 2023 | Details |
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance. | EIC Transition | € 1.881.875 | 2023 | Details |
Development of a lung METAstasis-on-a-CHIP model for osteosarcoma as a biomimetic testing platform for drug discovery and therapeutic innovationMETA-CHIP aims to develop a lung metastasis-on-a-chip model for osteosarcoma to enhance drug development and predict patient responses to therapies in real-time. | ERC STG | € 1.499.884 | 2024 | Details |
Automated canceR-on-A-CHip orgaN-specific metastatIc spreaDThe ARACHNID project aims to develop a multiplexed, automated tumor-metastasis-on-a-chip platform to enhance understanding and treatment of cancer metastasis, starting with pediatric tumors. | ERC POC | € 150.000 | 2024 | Details |
Nano-assisted digitalizing of cancer phenotyping for immunotherapy
The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.
Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)
Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance.
Development of a lung METAstasis-on-a-CHIP model for osteosarcoma as a biomimetic testing platform for drug discovery and therapeutic innovation
META-CHIP aims to develop a lung metastasis-on-a-chip model for osteosarcoma to enhance drug development and predict patient responses to therapies in real-time.
Automated canceR-on-A-CHip orgaN-specific metastatIc spreaD
The ARACHNID project aims to develop a multiplexed, automated tumor-metastasis-on-a-chip platform to enhance understanding and treatment of cancer metastasis, starting with pediatric tumors.